295 related articles for article (PubMed ID: 17227710)
1. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.
Kochanny MJ; Adler M; Ewing J; Griedel BD; Ho E; Karanjawala R; Lee W; Lentz D; Liang AM; Morrissey MM; Phillips GB; Post J; Sacchi KL; Sakata ST; Subramanyam B; Vergona R; Walters J; White KA; Whitlow M; Ye B; Zhao Z; Shaw KJ
Bioorg Med Chem; 2007 Mar; 15(5):2127-46. PubMed ID: 17227710
[TBL] [Abstract][Full Text] [Related]
2. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.
Ye B; Arnaiz DO; Chou YL; Griedel BD; Karanjawala R; Lee W; Morrissey MM; Sacchi KL; Sakata ST; Shaw KJ; Wu SC; Zhao Z; Adler M; Cheeseman S; Dole WP; Ewing J; Fitch R; Lentz D; Liang A; Light D; Morser J; Post J; Rumennik G; Subramanyam B; Sullivan ME; Vergona R; Walters J; Wang YX; White KA; Whitlow M; Kochanny MJ
J Med Chem; 2007 Jun; 50(13):2967-80. PubMed ID: 17536795
[TBL] [Abstract][Full Text] [Related]
3. 5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa.
Qiao JX; Cheng X; Modi DP; Rossi KA; Luettgen JM; Knabb RM; Jadhav PK; Wexler RR
Bioorg Med Chem Lett; 2005 Jan; 15(1):29-35. PubMed ID: 15582405
[TBL] [Abstract][Full Text] [Related]
4. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
5. Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa.
Mederski WW; Cezanne B; van Amsterdam C; Bühring KU; Dorsch D; Gleitz J; März J; Tsaklakidis C
Bioorg Med Chem Lett; 2004 Dec; 14(23):5817-22. PubMed ID: 15501047
[TBL] [Abstract][Full Text] [Related]
6. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
Quan ML; Han Q; Fevig JM; Lam PY; Bai S; Knabb RM; Luettgen JM; Wong PC; Wexler RR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1795-8. PubMed ID: 16434195
[TBL] [Abstract][Full Text] [Related]
7. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
[TBL] [Abstract][Full Text] [Related]
8. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
[TBL] [Abstract][Full Text] [Related]
9. Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
Qiao JX; King SR; He K; Wong PC; Rendina AR; Luettgen JM; Xin B; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2009 Jan; 19(2):462-8. PubMed ID: 19046881
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
Varnes JG; Wacker DA; Pinto DJ; Orwat MJ; Theroff JP; Wells B; Galemo RA; Luettgen JM; Knabb RM; Bai S; He K; Lam PY; Wexler RR
Bioorg Med Chem Lett; 2008 Jan; 18(2):749-54. PubMed ID: 18054227
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.
Zhang P; Bao L; Zuckett JF; Goldman EA; Jia ZJ; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Park G; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2004 Feb; 14(4):983-7. PubMed ID: 15013006
[TBL] [Abstract][Full Text] [Related]
12. Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.
Qiao JX; Wang TC; Wang GZ; Cheney DL; He K; Rendina AR; Xin B; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Sep; 17(18):5041-8. PubMed ID: 17643988
[TBL] [Abstract][Full Text] [Related]
13. N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.
Jia ZJ; Su T; Zuckett JF; Wu Y; Goldman EA; Li W; Zhang P; Clizbe LA; Song Y; Bauer SM; Huang W; Woolfrey J; Sinha U; Arfsten AE; Hutchaleelaha A; Hollenbach SJ; Lambing JL; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2004 May; 14(9):2073-8. PubMed ID: 15080981
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T
Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673
[TBL] [Abstract][Full Text] [Related]
15. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
[TBL] [Abstract][Full Text] [Related]
17. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
[TBL] [Abstract][Full Text] [Related]
18. Design of benzamidine-type inhibitors of factor Xa.
Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
[TBL] [Abstract][Full Text] [Related]
19. Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa.
Lopopolo G; Fiorella F; de Candia M; Nicolotti O; Martel S; Carrupt PA; Altomare C
Eur J Pharm Sci; 2011 Feb; 42(3):180-91. PubMed ID: 21112391
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
